back to Directory

RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation logo

Founded
2011
Patents
24
Clinical Trials
7
Publications
2

Technologies

RNA-focused Startups

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is developing the next generation of immuno-oncology therapeutics based on its novel RNAi therapeutic platform including self-delivering RNAi (sd-rxRNA®) compounds.


Posts Mentioning This Company

Top Companies At The Forefront Of RNA Therapeutics Development

  
Alongside the topic of gene editing technologies that keeps making headlines these days, there is also a wave of breakthroughs in the field of RNA-targeting medicines, primarily falling into the following two categories: antisense oligonucleotides (ASO), and RNA interference (RNAi) technologies. (another promising approach, dealing with editing RNA itself by …